This is an archive of papers published by the staff and faculty of Fox Chase Cancer Center. For questions about content, please contact Talbot Research Library
Last updated on
Janne PA , von Pawel J , Cohen RB , Crino L , Butts CA , Olson SS , Eiseman IA , Chiappori AA , Yeap BY , Lenehan PF , Dasse K , Sheeran M , Bonomi PD
Multicenter, randomized, phase II trial of CI-1033, an irreversible pan-ERBB inhibitor, for previously treated advanced non-small-cell lung cancer
Journal of Clinical Oncology. 2007 Sep;25(25) :3936-3944
AbstractPurpose To evaluate the efficacy of the pan-ERBB inhibitor, CI- 1033, in platinum- refractory or recurrent advanced-stage non-small-cell lung cancer ( NSCLC). Patients and Methods This open-label, randomized phase II trial evaluated CI- 1033 in patients with advanced- stage NSCLC who experienced treatment failure after or were refractory to platinum- based chemotherapy. Three oral CI- 1033 doses were evaluated in 21- day dosing cycles: 50 mg daily for 21 consecutive days, 150 mg daily for 21 consecutive days, and 450 mg daily for 14 consecutive days followed by 7 days of no treatment. The primary efficacy end point was the 1- year survival rate. Results One hundred sixty-six patients were randomly assigned to treatment. Baseline patient demographics were well balanced. The most common drug- related adverse events were rash and diarrhea. The 450- mg arm ( 14 days on/ 7 days off) was closed early due to an excessive rate of adverse events. The 1- year survival rates were 29%, 26%, and 29%, respectively, in the three arms. The response rates were 2%, 2%, and 4%, and stable disease was confirmed in 16%, 23%, and 18% of patients, respectively, in the three study arms. Exploratory analyses demonstrated a prolonged survival in patients who developed a rash and in those with baseline tumor ERBB-2 expression. Conclusion CI- 1033 had modest activity in unselected NSCLC patients but did not meet its primary end point. Future studies should focus on identifying methods of patient selection.
NotesISI Document Delivery No.: 209VL Times Cited: 0 Cited Reference Count: 39 Cited References: BAILEY R, 2003, LUNG CANCER, V41, P71 BARBACCI EG, 2003, CANCER RES, V63, P4450 BRABENDER J, 2001, CLIN CANCER RES, V7, P1850 BREATHNACH OS, 2001, J CLIN ONCOL, V19, P1734 BURTNESS B, 2005, J CLIN ONCOL, V23, P8646 CALVO E, 2004, CLIN CANCER RES, V10, P7112 CAPPUZZO F, 2005, J CLIN ONCOL, V23, P5007 CAPPUZZO F, 2005, J NATL CANCER I, V97, P643 CITRI A, 2002, EMBO J, V21, P2407 CLAMON G, 2005, CANCER, V103, P1670 DETRE S, 1995, J CLIN PATHOL, V48, P876 FONTANINI G, 1998, CLIN CANCER RES, V4, P241 FRY DW, 1998, P NATL ACAD SCI USA, V95, P12022 FUJIMOTO N, 2005, CANCER RES, V65, P11478 FUKUOKA M, 2003, J CLIN ONCOL, V21, P2237 HERBST RS, 2005, J CLIN ONCOL, V23, P5578 HIRSCH FR, 2002, BRIT J CANCER, V86, P1449 HIRSCH FR, 2005, J CLIN ONCOL, V23, P6838 JANNE PA, 2004, LUNG CANCER-J IASLC, V44, P221 KOBAYASHI S, 2005, NEW ENGL J MED, V352, P786 KRIS MG, 2003, JAMA-J AM MED ASSOC, V290, P2149 KRUG LM, 2005, CANCER, V104, P2149 KWAK EL, 2005, P NATL ACAD SCI USA, V102, P7665 LAI WW, 2001, ANN THORAC SURG, V72, P1868 LANGER CJ, 2004, J CLIN ONCOL, V22, P1180 LYNCH TJ, 2004, NEW ENGL J MED, V350, P2129 MILLER VA, 2004, J CLIN ONCOL, V22, P1103 NEMUNAITIS J, 2005, CLIN CANCER RES, V11, P3846 PAEZ JG, 2004, SCIENCE, V304, P1497 PAO W, 2004, P NATL ACAD SCI USA, V101, P13306 PEREZSOLER R, 2004, J CLIN ONCOL, V22, P3238 RUSCH V, 1993, CANCER RES, V53, P2379 RUSCH V, 1997, CLIN CANCER RES, V3, P515 SHEPHERD FA, 2005, NEW ENGL J MED, V353, P123 THATCHER N, 2005, LANCET, V366, P1527 THERASSE P, 2000, J NATL CANCER I, V92, P205 TSAO MS, 2005, NEW ENGL J MED, V353, P133 WAKELING AE, 2002, CANCER RES, V62, P5749 YI ES, 1997, MODERN PATHOL, V10, P142